Application of siRNA for targeted inhibition of lncRNA Gm26917 gene expression in preparation of acute lung injury medicine for treating sepsis
By targeting the inhibition of lncRNA Gm26917, the lack of targeted treatment in the treatment of acute lung injury in sepsis was solved, and a significant reduction in inflammatory factors and pulmonary edema was achieved, providing new treatment ideas with important clinical significance.
Patent Information
- Application Number
- CN202410988086.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective targeted treatment methods to control acute lung injury caused by sepsis, especially the role of lncRNA Gm26917 in this process is not clear, resulting in the main treatment of treatment to relieve symptoms and lack of targeted treatment.
Using siRNA targeting inhibition of lncRNA Gm26917, targeting the inhibition of Gm26917 expression in alveolar macrophages by designing specific siRNA sequences and using viruses or liposomes as vectors, reducing inflammatory factors expression levels, and reducing pulmonary edema and pathological damage.
It effectively reduces the expression of inflammatory factors in the acute lung injury model of sepsis, reduces pulmonary edema and pathological damage, improves the function and apoptosis of alveolar macrophages, and provides new targeted treatment ideas with significant clinical significance.
Smart Images

Figure CN118976041A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to an application of siRNA for targeted inhibition of lncRNA Gm26917 gene expression in the preparation of a drug for treating acute lung injury caused by sepsis. Background Art
[0002] As one of the three RNA treasures (miRNA, lncRNA and circRNA), lncRNA is a type of non-coding RNA molecule with a length of more than 200nt, which lacks an open reading frame (ORF) and has no protein coding function. A large number of experiments have confirmed that lncRNA is inseparable from the occurrence and development of human diseases. It can regulate gene expression at the epigenetic, cis or trans transcription and post-transcription levels, and participate in biological processes such as X chromosome silencing, genomic imprinting, chromatin modification, transcriptional activation, transcriptional interference, and nuclear transport. However, the number of disease-related lncRNAs identified by experiments is less than 1% of the identified loci, and its biological functions need to be further explored.
[0003] Sepsis is currently conceptualized as the result of an imbalanced systemic inflammatory response that affects immune function, the neuroendocrine axis, and coagulation, ultimately leading to organ damage. The original model of sepsis was an immune response to endotoxin, a lipopolysaccharide (LPS) found in the cell wall of Gram-negative bacteria, which is a good example of a pathogen-associated molecular pattern (PAMP). Innate immune cells, such as macrophages, have receptors that recognize different types of PAMPs. Toll-like receptors (TLRs) and lectin receptors on the cell surface recognize a variety of bacterial substances in the extracellular space. When bound to bacterial ligands, these receptors stimulate macrophages to produce tumor necrosis factor (TNF), interleukin-1β (IL-1β), and IL-6. These three proinflammatory cytokines generate a systemic inflammatory response that is characteristic of early sepsis.
[0004] Acute lung injury (ALI) is the damage of alveolar epithelial cells and capillary endothelial cells caused by various direct and indirect injury factors, resulting in diffuse interstitial and alveolar edema, leading to acute hypoxic respiratory insufficiency or respiratory failure. When the damage reaches a certain degree, acute respiratory distress syndrome (ARDS) may occur. Generally speaking, when we talk about lung injury, we will involve acute respiratory distress syndrome, so the two often appear together. ALI can be caused by a variety of clinical diseases. It can be divided into intrapulmonary factors (direct injury) and extrapulmonary factors (indirect injury) according to whether it is primary in the lung. The incidence of ARDS varies according to its cause. The incidence of ALI / ARDS can be as high as 25%~50% in severe infection, 40% in massive blood transfusion, and 11%~25% in multiple trauma. Although different studies have reported different mortality rates of ALI / ARDS (15~72%), the mortality rate of ARDS is still relatively high in general. At present, controlling the primary disease and curbing the uncontrolled systemic inflammatory response induced by it are necessary measures to prevent and treat ALI / ARDS. Although new treatments continue to emerge in clinical practice, some of which inhibit inflammatory factors and reduce inflammatory responses, some improve oxygenation and correct hypoxia, and some promote the absorption of fluid in the lungs, there is still a lack of targeted treatments. General treatments are still mainly focused on relieving symptoms, so it is crucial to study and identify potential targets and develop targeted drugs.
[0005] lncRNA Gm26917 is still an understudied lncRNA. Although the expression changes of Gm26917 have been identified in some immune-mediated diseases by transcriptome analysis, the detailed role of lncRNA Gm26917 remains unknown. For example, Hewitson et al. identified Th1-activated CD4 + Downregulation of Gm26917 in T cells. High-throughput sequencing also found that Gm26917 was enriched in the NLRP3 inflammasome. After ultrasound treatment of arthritic mice, the expression of Gm26917 was upregulated in T cells and B cells. Another study found that FOXM1 can bind to the promoter region of Gm26917 and directly regulate the transcription of Gm26917 in muscle satellite cells. The above studies all suggest that lncRNA Gm26917 can regulate biological functions, but whether it is involved in the occurrence and development of sepsis and the role it plays in it remains unclear.
[0006] After more than 20 years of research, siRNA has been recognized as a type of precision medicine therapy. Compared with other treatment methods, siRNA therapy has a series of advantages. siRNA is highly safe, efficient, highly specific, multifunctional, easy to synthesize, and has low production costs. At present, the delivery strategies of siRNA can be divided into two types. One is that the targeting part is directly covalently coupled to siRNA to form siRNA conjugates; the other is a delivery system based on various nanocarriers. The delivery platforms of siRNA include various lipids or lipidoids, peptides, polymers, exosomes, dendrimers, siRNA conjugates, etc. The chemical structures of the key components of the delivery platform include Dlin-DMA, Dlin-MC3-DMA, C12-200, cKK-E12, GalNAc-siRNA conjugates, MLP-based DPC2.0 (EX-1), PNP, PEI, PLGA, PTMS, GDDC4, PAsp (DET), etc. Summary of the invention
[0007] To achieve the above-mentioned purpose and other related purposes, the present invention provides an application of siRNA that targets and inhibits the expression of lncRNA Gm26917 gene in the preparation of a drug for treating acute lung injury in sepsis. The siRNA has the characteristics of high introduction efficiency, small dosage and rapid absorption. The biological preparation includes siRNA or its nucleic acid sequence modification and a carrier, the synthesized siRNA molecule is a modified siRNA molecule, and a pharmaceutically acceptable carrier is used, siRNA or its nucleic acid sequence modification inhibits the expression of lncRNA Gm26917, and the siRNA molecular carrier is selected from viruses and liposomes. Therefore, this siRNA that targets and inhibits the expression of lncRNAGm26917 gene can be used as a drug for the treatment of acute lung injury in sepsis. Based on the absorption, distribution, metabolism, excretion and drug interaction of the drug, the drug is administered by intravenous injection, which can quickly and effectively deliver the drug to the target organ to exert its effect. The purpose of the present invention is to provide an application of siRNA that targets and inhibits the expression of lncRNA Gm26917 gene in the preparation of a drug for treating acute lung injury in sepsis.
[0008] To achieve the above-mentioned purpose and other related purposes, the technical solution provided by the present invention is: the use of siRNA that targets and inhibits the expression of lncRNA Gm26917 gene in the preparation of a drug for treating acute lung injury caused by sepsis.
[0009] The preferred technical solution is: the nucleotide sequence of the siRNA is: si lncRNA Gm26917-1: 5'-CAAAACCAACCCGGTGAGC-3'; si lncRNA Gm26917-2: 5'-GCUCACCGGGUUGGUUUUG-3'.
[0010] To achieve the above-mentioned purpose and other related purposes, the technical solution provided by the present invention is: a pharmaceutical composition for treating acute lung injury caused by sepsis, comprising siRNA that targets and inhibits lncRNA Gm26917, wherein the nucleotide sequence of the siRNA is: si lncRNA Gm26917-1: 5'-CAAAACCAACCCGGTGAGC-3'; si lncRNA Gm26917-2: 5'-GCUCACCGGGUUGGUUUUG-3'.
[0011] The preferred technical solution is: further comprising a pharmaceutically acceptable carrier.
[0012] Due to the application of the above technical solution, the present invention has the following advantages compared with the prior art: The present invention uses siRNA to target and inhibit lncRNA Gm26917 in alveolar macrophages to reduce the mRNA expression level of inflammatory factors in the acute lung injury model of sepsis. At the same time, the chemotaxis and phagocytic ability of alveolar macrophages are also significantly reduced; in addition, the use of siRNA to target and inhibit lncRNA Gm26917 weakens the vitality of alveolar macrophages and the apoptosis of alveolar macrophages is also significantly improved. The present invention also uses siRNA sequence design to synthesize lentivirus (LV-sh-Gm26917) to target and inhibit the expression of lncRNA Gm26917 in mouse lung tissue. LV-sh-Gm26917 can not only reduce the pulmonary edema of mice with acute lung injury, but also reduce the pathological damage of mouse lung tissue and reduce the infiltration of alveolar macrophages. The above findings also indicate that this siRNA that targets and inhibits the expression of the lncRNA Gm26917 gene has important development and application prospects in the treatment of acute lung injury in sepsis, and provides a new idea for the clinical treatment of acute lung injury in sepsis, which has significant clinical significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 The expression of lncRNA Gm26917 was significantly upregulated in the acute lung injury model of LPS-induced sepsis.
[0014] Figure 2 The expression of lncRNA Gm26917 was significantly upregulated in the CLP-induced sepsis acute lung injury model.
[0015] Figure 3si lncRNA Gm26917 significantly reduced the expression level of lncRNA Gm26917 in alveolar macrophages.
[0016] Figure 4 si lncRNA Gm26917 significantly inhibited the expression levels of inflammatory factors in alveolar macrophages.
[0017] Figure 5 si lncRNA Gm26917 significantly reduced the chemotactic ability of M1 macrophages and enhanced the chemotactic ability of M2 macrophages.
[0018] Figure 6 si lncRNA Gm26917 significantly inhibited the phagocytic ability of M1 macrophages and enhanced the phagocytic ability of M2 macrophages.
[0019] Figure 7 si lncRNA Gm26917 significantly inhibited the cell viability of alveolar macrophages.
[0020] Figure 8 si lncRNA Gm26917 significantly reduced the apoptosis of alveolar macrophages.
[0021] Fig. 9 LV-sh-Gm26917 significantly reduced lung inflammation in mice with acute lung injury.
[0022] Among them, “*” represents P<0.05; “**” represents P<0.01; “***” represents P<0.001. DETAILED DESCRIPTION
[0023] The following is a description of the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in the embodiments.
[0024] See also Figure 1-9 . It should be noted that the structures, proportions, sizes, etc. illustrated in the drawings of this specification are only used to match the contents disclosed in the specification for people familiar with this technology to understand and read, and are not used to limit the limiting conditions under which the present invention can be implemented. Therefore, they have no substantive technical significance, and any structural modification, change in proportional relationship or adjustment of size. The following examples are provided to better understand the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are all conventional methods unless otherwise specified. The experimental materials used in the following examples are all purchased from conventional biochemical reagent stores unless otherwise specified.
[0025] In the specific embodiments of the present invention, the experiments were repeated at least 3 times, and the result data were expressed as mean ± standard deviation. The prism statistical software was used for statistical analysis. The difference between the two was tested by t test, and it was considered statistically significant when P < 0.05.
[0026] Example 1: Establishment of a sepsis-induced acute lung injury model using LPS induction and CLP methods Experimental animals: Male 6-8 week old C57BL / 6 mice (1) Tracheal instillation of lipopolysaccharide model First, LPS solution was prepared, and then LPS solution (concentration of 10 mg / kg) was instilled into the trachea of mice, and the control group was injected with an equal volume of PBS. The mice were killed 2 hours later, and the lung tissues of the mice were removed for subsequent operations.
[0027] (2) Cecal ligation and puncture (CLP) model ① Animal grouping: The animals were randomly divided into 2 groups, a control group and a model group. The model group was treated with cecal ligation and puncture, while the control group received no treatment.
[0028] ② Anesthetize the mouse with isoflurane, remove the abdominal hair with an electric shaver, and disinfect the area with iodine.
[0029] ③ Use a scalpel to longitudinally incise the midline of the skin, identify the white line of the abdominal muscle tissue (middle white fascia), and dissect it to perform intermuscular incisions and incisions of the fascial and peritoneal layers. Use blunt dissecting forceps to locate the cecum, separate the cecum and externalize it, leaving the rest of the small and large intestines in the peritoneal cavity. In most cases, the cecum is located on the left side of the abdomen.
[0030] ④ Ligate the cecum at the designated location to achieve the desired severity level.
[0031] ⑤ Before cecal perforation, gently push the cecal contents toward the distal end of the cecum, and gently aspirate any trapped air or gas as the cecum is perforated. The cecum is perforated in the mesenteric to anterior direction in a single and full perforation manner midway between the ligature and the tip of the cecum.
[0032] ⑥ After the needle is removed, squeeze out a small amount (droplets) of feces from the mesenteric and anti-mesenteric penetration holes to ensure patency.
[0033] ⑦ Reposition the cecum into the abdominal cavity without spreading feces in the cecum to the edge of the abdominal wall wound.
[0034] ⑧ Close the peritoneum, fascia, and abdominal muscle tissue with simple continuous sutures. Use metal clips or simple interrupted sutures to close the skin.
[0035] Example 2: Extraction of total RNA from tissues, cDNA synthesis and qPCR detection 2.1 Total RNA extraction from tissues 1. Take out the sample from the -80℃ refrigerator, take an appropriate amount of tissue (about 10 mg) and place it in a 5 ml EP tube, add 500 μl Trizol to immerse the tissue, grind the tissue (20-30 s) with an electric rotor (3 gear) until it is crushed (wash the rotor with water once between each sample to reduce cross contamination), transfer to a 1.5 ml RNase-free EP tube, and add 500 μl Trizol. Place on ice for lysis for 5 min (pre-cool the centrifuge to 4 degrees in advance).
[0036] 2. Add 200 μl chloroform (1 / 5 of the volume of Trizol), shake vigorously (milky red), and let stand on ice for 10 min.
[0037] 3. Place in a pre-cooled centrifuge and centrifuge (4 degrees, 12000 rpm, 15 min). Three distinct layers can be seen (the upper colorless and transparent aqueous phase is the RNA layer, the very thin milky white layer in the middle is the DNA layer, the lower red layer is the protein layer, and large tissue precipitates can be seen at the bottom).
[0038] 4. Carefully and slowly aspirate the supernatant, about 400 μl (it is better to aspirate less than more), and place it in another new 1.5 ml RNase-free EP tube. Add an equal volume of isopropanol, invert upside down to mix, and let it stand at room temperature for 15 min.
[0039] 5. Centrifuge (4 degrees, 12000 rpm, 15 min), and a white precipitate will be visible (generally the tissue precipitate is larger).
[0040] 6. Discard the supernatant, add 950 μl of 75% ethanol to each tube, and mix by inverting the tubes (remember not to use a gun to mix, as this will cause the RNA to dissolve).
[0041] 7. Centrifuge (4 degrees, 12000 rpm, 10 min), and a clear white precipitate can be seen (tissue precipitates are generally larger).
[0042] 8. After centrifugation, discard the supernatant, put it into the centrifuge for another quick spin, wash away the residual liquid with a 10 μl pipette, open the lid and let it dry (about 5 min).
[0043] 9. Add an appropriate amount of DEPC water (usually 30-50 μl) to each tube according to the size of the precipitate, dissolve the RNA by pipetting, measure the concentration using an enzyme marker, mark the OD value (260 / 280=1.8-2.0), and store at -80°C.
[0044] 2.2 cDNA synthesis: 1) Calculate the volume X corresponding to 2 μg of RNA based on the measured RNA concentration.
[0045] 2) Reverse transcription system: Component volume (μl) 4x PrimeScript RT Master 5; RNA X; Make up to 20 μl with RNAase free H2O 3) Reaction conditions: Add the prepared system to a water bath, incubate at 37°C for 15 minutes, then at 85°C for 5 seconds. Take out the reverse transcribed cDNA and store it at -80°C.
[0046] 2.3 Real-time fluorescence quantitative PCR 1) Take out the cDNA stored in the -80℃ refrigerator and thaw it on ice, then dilute it with ddH2O at a ratio of 1:3; 2) Prepare the reaction system according to the TOYOBO SYBR Green enzyme instructions as follows: Component volume (μl) SYBR Green enzyme 10; Upstream primer 0.8; Downstream primer 0.8; ddH2O 7.4; cDNA 1; The primer sequences are as follows: Gapdh F: TTCACCACCATGGAGAAGGC; Gapdh R: GGCATGGACTGTGGTCATGA; Gm26917 F: GCAATTATTCCCCATGAACG; Gm26917 R: GGCCTCACTAAACCATCCAA; IL-1β F: CTGAACTCAACTGTGAAATGC; IL-1β R: TGATGTGCTGCTGCGAGA; IL-6 F: ACACATGTTCTCTGGGAAATCGT; IL-6 R: AAGTGCATCATCGTTGTTCATACA; TNF-α F:ACTGGCAGAAGAGGCACTC; TNF-α R:CTGGCACCACTAGTTGGTTG; IL-10 F: TGGCCCAGAAATCAAGGAGC; IL-10 R: CAGCAGACTCAATACACACT; IL-12β F: TGGTTTGCCATCGTTTTGCTG; IL-12β R: ACAGGTGAGGTTCACTGTTTCT; Ccl2 F:CCAGCAAGATGATCCCAATG; Ccl2 R:TACGGGTCAACTTCACATTC; Ccl4 F:TTTCTCTTACACCTCCCGGC; Ccl4 R:AGCTGCTCAGTTCAACTCCA; Ccl24 F:CTCCTTCTTCCTGGTAGCCTG; Ccl24 R:ATGGCCCTTCTTGGTGATGA; Cxcl2 F:ACCAACCACCAGGCTACA; Cxcl2 R:TCAGGGTCAAGGCAAACT; Cxcl10 F:TCATCCCTGCGAGCCTATCC; Cxcl10 R:TGCGTGGCTTCACTCCAGTT; Axl F:ATGGCCGACATTGCCAGTG: Axl R:CGGTAGTAATCCCCGTTGTAGA; Gpnmb F:CATTCCCATCTCGAAGGTGAAA; Gpnmb R:AAATGGCAGAGTCGTTGAGGA; Label F:CAGGGCCTTTACCAGGGAGA; Mertk R:TGTGTGCTGGATGTGATCTTC; Macro F:ACAGAGCCGATTTTGACCAAG; Macro R:CAGCAGTGCAGTACCTGCC: Trem2 F:CTGGAACCGTCACCATCACTC; Trem2 R:CGAAAACTCGATGACTCCTCGG; CD36 F: ATGGGCTGTGATCGGAACTG; CD36 R: GTCTTCCCAATAAGCATGTCTCC.
[0047] 3) Add the samples into the eight-tube strips in a certain order, and set up three secondary wells for each sample to avoid errors caused by sample loading.
[0048] 4) Cover the tubes, centrifuge and mix to remove bubbles in the eight-tube strip, and then place them in the qPCR instrument. The procedure is as follows: Step Temperature (°C) Time (s) Cycle Number 1 90 30 1 2 95 5 2-4, 39 x cycle 3 60 30 4 65 5 5 95 0.5℃ / cycle 5) After the run, export the data and analyze it, calculate the 2-△△CT of the sample, and analyze the expression of each target gene at the mRNA level.
[0049] Figure 1 , Figure 2 The results showed that in the LPS and CLP models, the expression of Gm26917 was significantly increased in the acute lung injury model of sepsis.
[0050] Example 3: Knockdown of Gm26917 using siRNA in MH-S cells (mouse alveolar macrophage cell line) to verify that knockdown of Gm26917 can reduce the inflammatory response in acute lung injury caused by sepsis 3.1 Cell transfection Take jetPRIME® reagent for transfection of MH-S cells as an example. The steps are as follows: (1) Add 2.5 μl siRNA to 200 μl JetPRIME buffer, vortex for 10 s, and centrifuge for 2 s. (2) Add 4 μl of JetPRIME reagent, vortex for 10 s, and spin at reduced speed; (3) Incubate at room temperature for 10 to 15 minutes; (4) Add the transfection mixture dropwise into the cells in serum-containing culture medium in a "M" shape; (5) Gently rock the six-well plate back and forth, from side to side, and incubate at 37°C. (6) After 24 hours, the transfection medium was replaced with cell growth medium. 48 hours after transfection, the cells were harvested for subsequent experiments.
[0051] 3.2 LPS stimulation of cells The initial concentration of LPS was 1 mg / ml, which was diluted 100 times with complete medium, and 160 μl of the diluted LPS solution was added to each well of the six-well plate to reach a stimulation concentration of 800 ng / ml. After 12 hours, the cells were collected for subsequent operations.
[0052] 3.3 Extraction of total cellular RNA ①Take out the cells cultured in the 6-well plate from the incubator, discard the culture medium, wash three times with phosphate buffered saline (PBS) precooled on ice, and discard the PBS. Add 500 ml of lysis buffer reagent to lyse the cells, then add 500 ml of anhydrous ethanol and transfer the cell lysate to the centrifuge column. Then centrifuge at 4℃, 4000 g for 1 min. ③Add 500 ml of Wash Buffer, centrifuge at 4℃, 12000 g for 1 min, discard the lower layer of centrifuge, centrifuge in an empty tube under the same conditions for 1 min, and retain the RNA precipitate. Transfer the centrifuge column to an enzyme-free 1.5 ml centrifuge tube, open the lid and dry for 2 min. ④Add 20-30 μl of Elution Buffer, let it stand for 2 min, then centrifuge at 4℃, 12000 g for 1 min, add the centrifuge to the centrifuge column again, let it stand for 5 min, then centrifuge at 4℃, 12000 g for 1 min. After measuring the concentration, mark it and store it in a -80℃ ultra-low temperature refrigerator.
[0053] 3.4 Real-time fluorescence quantitative PCR See Example 2 for details Figure 3 , 4 , 5, 6 are the results of Example 3: Figure 3 The results showed that siRNA successfully silenced the expression of Gm26917, and its expression was upregulated after LPS stimulation.
[0054] Figure 4 The results showed that in alveolar macrophages, before and after LPS treatment, the above-mentioned siRNA targeted inhibition of Gm26917 reduced the expression of pro-inflammatory factors and increased the expression of anti-inflammatory factors.
[0055] Figure 5 The results showed that in alveolar macrophages, before and after LPS treatment, the above-mentioned siRNA targeted inhibition of Gm26917 reduced the expression of chemokines secreted by M1 macrophages and increased the expression of chemokines secreted by M2 macrophages.
[0056] Figure 6 The results showed that in alveolar macrophages, before and after LPS treatment, the above-mentioned siRNA targeted inhibition of Gm26917 significantly inhibited the phagocytic ability of M1 macrophages and enhanced the phagocytic ability of M2 macrophages.
[0057] Taken together, the above results verified that knocking down Gm26917 can reduce the inflammatory response in acute lung injury caused by sepsis.
[0058] Example 4: Knockdown of Gm26917 by siRNA to verify its ability to inhibit alveolar macrophage activity 4.1 CCK-8 analysis of cell viability (1) Prepare 100 μl of cell suspension in a 96-well plate and pre-incubate the plate in an incubator for 24 hours (at 37°C, 5% CO2).
[0059] (2) Add 10 μl of CCK-8 solution to each well (be careful not to create bubbles in the wells as they will affect the OD reading.
[0060] (3) Incubate the culture plate in an incubator for 2-4 hours.
[0061] (4) Measure the absorbance at 450 nm using an enzyme-labeled instrument.
[0062] Figure 7 The results of Example 4 are as follows: in macrophages, before and after LPS treatment, the above siRNA targeted inhibition of Gm26917 significantly inhibited the cell viability of alveolar macrophages.
[0063] Example 5: Knockdown of Gm26917 by siRNA to verify its ability to inhibit cell apoptosis 5.1 Flow cytometry analysis of alveolar macrophage apoptosis (1) Collect cells: discard the old culture medium, wash with 1× PBS, scrape the cells with a cell scraper and add them to a 1.5 ml EP tube, 2000 rpm, 10 min; (2) Preparation of single-cell suspension: discard the supernatant and wash twice with cold 1× PBS; (3) Resuspend the cells in 400 μl of 1X Annexin V Binding Buffer to a concentration of approximately 1×106 cells / ml.
[0064] (4) Add 5 μl of Annexin V-FITC staining solution to the cell suspension, mix gently, and incubate at 2-8°C in the dark for 15 minutes; (5) Add 5-10 μl of PI staining solution, mix gently, and incubate at 2-8°C in the dark for 2-5 minutes.
[0065] (6) Immediately detect using flow cytometry or fluorescence microscopy.
[0066] Figure 8 The results of Example 5 are as follows: in alveolar macrophages, before and after LPS treatment, the above siRNA targeted inhibition of Gm26917 significantly reduced the apoptosis of alveolar macrophages.
[0067] Example 6: Gm26917 was knocked down by tail vein injection of LV-sh-Gm26917 to verify that it can reduce lung inflammation in mice with acute lung injury.
[0068] 6.1 Tail vein injection and LPS stimulation After one week of acclimatization, C57BL / 6 mice were injected with lentivirus (LV-sh-NC or LV-sh-Gm26917, 1 ×109 TU / ml) through the tail vein, and the virus infection time was 72 hours. LPS stimulation was given 72 hours later to establish an acute lung injury model. The mice were first anesthetized by intraperitoneal injection of 10% chloral hydrate solution, and then LPS (10 mg / kg) was stimulated by tracheal instillation. The control group was given the same volume of PBS. After administration, the mice were placed vertically and slowly shaken for 1 minute to evenly distribute LPS or PBS in the left and right lungs of the mice. The mice were killed 12 hours later, and the intact left lung was taken to measure the W / D ratio of the lung, the upper lobe of the right lung was taken for paraffin embedding, and the remaining lung tissue was stored in a -80 degree Celsius refrigerator.
[0069] 6.2 Lung wet-to-dry ratio The intact left lung of the mouse was taken, washed with PBS and weighed for wet weight. The lung tissue was then freeze-dried and weighed for dry weight. Finally, the ratio of wet weight to dry weight was used to evaluate the pulmonary edema of the mouse.
[0070] 6.3 HE staining Lung tissue was removed from the killed mice and immersed in 4% paraformaldehyde. Then it was embedded in paraffin. The obtained paraffin sections were dewaxed and stained with eosin and hematoxylin. Finally, the stained sections were dehydrated with ethanol, transparentized with xylene and sealed with neutral gum. The pathological damage of the lung tissue was observed under a microscope.
[0071] 6.4 Immunohistochemical staining First, the embedded paraffin sections were dewaxed, and the lung tissue antigens were repaired with sodium citrate repair solution, and the endogenous peroxidase was inactivated with 3% hydrogen peroxide. Then, 10% goat serum was added to block the sections and antibodies were applied. After overnight, the sections were stained with DAB solution and hematoxylin nuclear staining. Finally, the images were observed and analyzed under a microscope. Five fields of view were observed for each sample and the number of positive cells was calculated.
[0072] Fig. 9 The results of Example 6 are as follows: In Figure A, after tail vein injection of LV-sh-Gm26917, the mRNA level of Gm26917 was significantly downregulated before and after LPS treatment; in Figure B, tail vein injection of LV-sh-Gm26917 to knock down Gm26917 can significantly improve the pulmonary edema in mice; in Figures C and D, tail vein injection of LV-sh-Gm26917 to knock down Gm26917 significantly reduced the secretion of inflammatory factors in the mouse lungs; in Figure E, tail vein injection of LV-sh-Gm26917 to knock down Gm26917 significantly reduced the pathological damage of mouse lung tissue and the infiltration of macrophages; Figures F and G are quantitative statistics of Figure E.
[0073] The inventors of the present invention have found that the use of siRNA to target and inhibit lncRNA Gm26917 in alveolar macrophages can reduce the mRNA expression level of inflammatory factors in the acute lung injury model of sepsis. At the same time, the chemotaxis and phagocytic ability of alveolar macrophages have also been significantly reduced; in addition, the use of siRNA to target and inhibit lncRNA Gm26917 weakens the vitality of alveolar macrophages and the apoptosis of alveolar macrophages has also been significantly improved. The present invention also uses siRNA sequence design to synthesize lentivirus (LV-sh-Gm26917) to target and inhibit the expression of lncRNA Gm26917 in mouse lung tissue. The inventors of the present invention have found that LV-sh-Gm26917 can not only reduce the pulmonary edema of mice with acute lung injury, but also reduce the pathological damage of mouse lung tissue and reduce the infiltration of alveolar macrophages. The above findings also indicate that this siRNA that targets and inhibits the expression of the lncRNA Gm26917 gene has important development and application prospects in the treatment of acute lung injury caused by sepsis, and provides a new idea for the clinical treatment of sepsis, which has significant clinical significance.
[0074] lncRNA Gm26917-seq:
[0075] The above description is only used to explain the preferred embodiments of the present invention, and is not intended to limit the present invention in any form. Therefore, any modifications or changes made to the present invention under the same inventive spirit should still be included in the scope of protection intended by the present invention.
Claims
1. Application of siRNA targeting and inhibiting the expression of lncRNA Gm26917 gene in the preparation of a drug for treating acute lung injury caused by sepsis.
2. The use of the siRNA targeting and inhibiting the expression of the lncRNA Gm26917 gene according to claim 1 in the preparation of a drug for treating acute lung injury caused by sepsis, characterized in that: The nucleotide sequence of the siRNA is: si lncRNA Gm26917-1: 5'-CAAAACCAACCCGGTGAGC-3'; si lncRNA Gm26917-2: 5'-GCUCACCGGGUUGGUUUUG-3'.
3. A pharmaceutical composition for treating acute lung injury caused by sepsis, characterized in that: It includes siRNA that targets and inhibits lncRNA Gm26917, and the nucleotide sequence of the siRNA is: si lncRNA Gm26917-1: 5'-CAAAACCAACCCGGTGAGC-3'; si lncRNA Gm26917-2: 5'-GCUCACCGGGUUGGUUUUG-3'.
4. The pharmaceutical composition for treating acute lung injury caused by sepsis according to claim 1, characterized in that: Also included are pharmaceutically acceptable carriers.
Citation Information
Patent Citations
Inhibition of Bruton's Tyrosine Kinase (Btk) in the Lung to Treat Severe Lung Inflammation and Lung Injury
US20170175125A1
HMGB1 antagonist treatment of acute lung injury
US20200354418A1
Compositions and methods for modulating and detecting tissue specific th17 cell pathogenicity
US20210102166A1
AU2022400971A1
